Compare ECL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECL | ARGX |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5B | 52.6B |
| IPO Year | N/A | 2017 |
| Metric | ECL | ARGX |
|---|---|---|
| Price | $281.30 | $818.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $295.00 | ★ $979.22 |
| AVG Volume (30 Days) | ★ 1.0M | 353.9K |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 6.95 | ★ 23.27 |
| Revenue | ★ $15,890,400,000.00 | $3,683,281,000.00 |
| Revenue This Year | $3.04 | $91.44 |
| Revenue Next Year | $6.03 | $36.90 |
| P/E Ratio | $40.51 | ★ $32.78 |
| Revenue Growth | 1.38 | ★ 92.98 |
| 52 Week Low | $221.62 | $510.06 |
| 52 Week High | $286.04 | $934.62 |
| Indicator | ECL | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 46.64 |
| Support Level | $271.22 | $781.07 |
| Resistance Level | $282.47 | $818.78 |
| Average True Range (ATR) | 4.97 | 24.70 |
| MACD | 1.09 | 3.55 |
| Stochastic Oscillator | 94.75 | 73.52 |
Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.